A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo-Controlled Trial To Evaluate The Effects Of 100 MG Once Daily Of Eplerenone On Serum Aldesterone And Plasma Renin Activity During 10 Days Of Dosing In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Eplerenone (Primary)
- Indications Heart failure; Hypertension
- Focus Pharmacodynamics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2009 Additional location identified as reported by ClinicalTrials.gov.
- 20 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.